Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Compugen Ltd.
DescriptionPeptide identified using the Protein-Protein Interactions Blockers Platform that is predicted to inhibit a specific protein-protein interaction occurring in a protein target expressed on neutrophils and monocytes
Molecular Target
Mechanism of Action 
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPreclinical
Standard IndicationSepsis
Indication DetailsTreat septic shock
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today